Literature DB >> 12623121

Radiolabeling morpholinos with 90Y, 111In, 188Re and 99mTc.

Chang-bin Liu1, Guo-zheng Liu, Ning Liu, Yu-min Zhang, Jiang He, Mary Rusckowski, Donald J Hnatowich.   

Abstract

UNLABELLED: This laboratory is investigating morpholinos (MORF), a DNA analogue, for radiopharmaceutical applications. While we routinely radiolabel with (99m)Tc, we have now labeled MORFs with (111)In, (188)Re and (90)Y in anticipation of therapeutic studies.
METHODS: A 25 mer MORF with a primary amine on the 3' equivalent end attached via a 10 member linker was conjugated with an isothiocyanate backbone derivative of DOTA (for labeling with (111)In and (90)Y) and with NHS-MAG(3) (for labeling with (188)Re and (99m)Tc). The in vitro stability of labeled MORFs were investigated and biodistribution was carried out in normal mice.
RESULTS: As evident by size exclusion HPLC, ITLC and Sep-Pak analysis, all four radiolabeled MORFs were successfully radiolabeled. In each case, the labeled MORFs showed one sharp peak in HPLC that shifted completely to earlier retention times following addition of a polymer conjugated with the complementary MORF. In saline at room temperature and in 37 degrees C serum, the radioactivity profile of (111)In, (188)Re and (99m)Tc was unchanged over 48 h while over the same period, the (90)Y profile showed a pronounced lower molecular weight peak which did not shift and was shown to be most probably due to (90)Y-DOTA resulting from radiolysis. In addition, the recovery of (188)Re on HPLC decreased as samples aged probably due to oxidation to perrhenate which was retained by the HPLC column. The biodistributions at 1, 3 and 6 h in normal mice showed no important differences among all four labels with the exception that levels of radioactivity in stomach and thyroid were higher in the case of (188)Re due to in vivo oxidation of the radiolabel to perrhenate.
CONCLUSIONS: When radiolabeled with DOTA, (90)Y-labeled MORF showed increased instabilities relative to that of (111)In and when radiolabeled with MAG(3), (188)Re showed in vitro and in vivo instabilities compared to (99m)Tc, but all labels were still largely intact after 48 h in saline or serum. Possibly because of the rapid clearance of MORFs, no important differences in biodistribution among (90)Y, (111)In and (99m)Tc labels were evident in normal mice. These strategies for labeling MORF with (90)Y and (188)Re therefore appear to be suitable for therapeutic applications although both show some evidence of instabilities.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12623121     DOI: 10.1016/s0969-8051(02)00389-x

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  11 in total

1.  Preparation of (111)In-DTPA morpholino oligomer for low abdominal accumulation.

Authors:  Guozheng Liu; Shuping Dou; Mary Rusckowski; Dale Greiner; Donald Hnatowich
Journal:  Appl Radiat Isot       Date:  2010-03-06       Impact factor: 1.513

2.  Metal-containing and related polymers for biomedical applications.

Authors:  Yi Yan; Jiuyang Zhang; Lixia Ren; Chuanbing Tang
Journal:  Chem Soc Rev       Date:  2016-02-24       Impact factor: 54.564

3.  Radiolabeling of MAG3-morpholino oligomers with 188Re at high labeling efficiency and specific radioactivity for tumor pretargeting.

Authors:  Guozheng Liu; Shuping Dou; Jiang He; Dongguang Yin; Suresh Gupta; Surong Zhang; Yi Wang; Mary Rusckowski; Donald J Hnatowich
Journal:  Appl Radiat Isot       Date:  2006-05-30       Impact factor: 1.513

4.  90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy.

Authors:  Guozheng Liu; Shuping Dou; Yuxia Liu; Yuzhen Wang; Mary Rusckowski; Donald J Hnatowich
Journal:  Bioconjug Chem       Date:  2011-11-03       Impact factor: 4.774

5.  Pretargeted radioimmunotherapy for hematologic and other malignancies.

Authors:  Roland B Walter; Oliver W Press; John M Pagel
Journal:  Cancer Biother Radiopharm       Date:  2010-04       Impact factor: 3.099

6.  Unexpected side products in the conjugation of an amine-derivatized morpholino oligomer with p-isothiocyanate benzyl DTPA and their removal.

Authors:  Guozheng Liu; Shuping Dou; Yuxia Liu; Minmin Liang; Ling Chen; Dengfeng Cheng; Dale Greiner; Mary Rusckowski; Donald J Hnatowich
Journal:  Nucl Med Biol       Date:  2010-10-27       Impact factor: 2.408

7.  (186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours.

Authors:  Anna Orlova; Thuy A Tran; Torun Ekblad; Amelie Eriksson Karlström; Vladimir Tolmachev
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-22       Impact factor: 9.236

8.  Sequence-specific DNA strand cleavage by 111In-labeled peptide nucleic acids.

Authors:  Yujian He; Igor G Panyutin; Alex Karavanov; Vadim V Demidov; Ronald D Neumann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-05       Impact factor: 9.236

9.  Preparation and properties of 99mTc(CO)3+-labeled N,N-bis(2-pyridylmethyl)-4-aminobutyric acid.

Authors:  Guozheng Liu; Shuping Dou; Jiang He; Jean-Luc Vanderheyden; Mary Rusckowski; Donald J Hnatowich
Journal:  Bioconjug Chem       Date:  2004 Nov-Dec       Impact factor: 4.774

Review 10.  Nanostructures as Radionuclide Carriers in Auger Electron Therapy.

Authors:  Nasrin Abbasi Gharibkandi; Joanna Gierałtowska; Kamil Wawrowicz; Aleksander Bilewicz
Journal:  Materials (Basel)       Date:  2022-02-01       Impact factor: 3.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.